Ruxolitinib withdrawal

Authors:

Publish Date: 2014/12/20

Volume: 1532, Issue: 1, Pages: 179-179

PDF Link

Abstract

Five patients developed various toxicities including headache thrombocytopenia anaemia and/or renal insufficiency during treatment with ruxolitinib and developed relapse of myelofibrosis systemic inflammatory response syndrome renal insufficiency respiratory distress anaemia thrombocytopenia splenic infarct disseminated intravascular coagulation like syndrome and/or polyarticular arthritis after withdrawal of ruxolitinib routes not stated not all outcomes stated One of these 5 patients died due to comorbidities

Keywords: